LAUSANNE, Switzerland I LONDON, UK & MURRAY HILL, NJ, USA I December 6, 2015 I ADC Therapeutics (ADCT), the oncology drug development company, today presented pre-clinical results for both ADCT-301 and ADCT-402, its novel Antibody Drug Conjugates (ADCs) in hematological tumours at the 57th American Society of Hematology (ASH) Annual Meeting, December 5-8, in Orlando, Florida.
ADCT-301 is currently in Phase I for lymphoma and leukemia. Yesterday ADCT announced that it has received IND clearance from the FDA to begin two Phase I clinical trials with ADCT-402 in hematological tumors.
ADCT-301 combines HuMax®-TAC, a human monoclonal antibody targeting CD25 (the alpha chain of the IL-2 receptor) created by Genmab A/S, with a dimeric pyrrolobenzodiazepine (PBD) warhead. The data confirm the mechanism of action of ADCT-301 and provide relevant pharmacodynamic assays for use in clinical development.
ADCT-402 is an anti-CD19 PBD-conjugate, with presented data demonstrating potent and specific in vitro and in vivo anti-tumor activity against CD19-positive hematological tumors as well as excellent tolerability.
Dr Patrick van Berkel, Senior Vice President Research & Development at ADC Therapeutics, said: “We are highly encouraged by these data which demonstrate the potential of ADCT-301 and ADCT-402. As we continue development, early indications are that our PBD-based ADCs could offer superior efficacy with a reduced resistance profile for the treatment of hematological tumors.”
The pre-clinical studies referenced above were conducted jointly by ADC Therapeutics, Spirogen (a division of AstraZeneca) and University College London, London.
ENDS
Notes to Editors
About ADC Therapeutics (www.adctherapeutics.com)
ADC Therapeutics SA (ADCT) is an oncology drug development company that specializes in the development of proprietary ADCs targeting major solid and hematological cancers. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to surface antigens present on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. The Company has access to warhead and linker chemistries via agreements with Spirogen (a wholly-owned subsidiary of AstraZeneca’s MedImmune). It is progressing eleven ADC programs, two of these under a joint development agreement with MedImmune. Its lead program, ADCT-301 for lymphoma and leukemia entered Phase I in 2015.
ADC Therapeutics has its head office in Lausanne, Switzerland and through subsidiaries has its R&D laboratories in London, UK, its clinical development team in New Jersey, USA, and its manufacturing team based in San Francisco, USA.
With its industry leading management team and board of directors, ADC Therapeutics is a leader in the development of PBD-based ADCs.
SOURCE: ADC Therapeutics
Post Views: 119
LAUSANNE, Switzerland I LONDON, UK & MURRAY HILL, NJ, USA I December 6, 2015 I ADC Therapeutics (ADCT), the oncology drug development company, today presented pre-clinical results for both ADCT-301 and ADCT-402, its novel Antibody Drug Conjugates (ADCs) in hematological tumours at the 57th American Society of Hematology (ASH) Annual Meeting, December 5-8, in Orlando, Florida.
ADCT-301 is currently in Phase I for lymphoma and leukemia. Yesterday ADCT announced that it has received IND clearance from the FDA to begin two Phase I clinical trials with ADCT-402 in hematological tumors.
ADCT-301 combines HuMax®-TAC, a human monoclonal antibody targeting CD25 (the alpha chain of the IL-2 receptor) created by Genmab A/S, with a dimeric pyrrolobenzodiazepine (PBD) warhead. The data confirm the mechanism of action of ADCT-301 and provide relevant pharmacodynamic assays for use in clinical development.
ADCT-402 is an anti-CD19 PBD-conjugate, with presented data demonstrating potent and specific in vitro and in vivo anti-tumor activity against CD19-positive hematological tumors as well as excellent tolerability.
Dr Patrick van Berkel, Senior Vice President Research & Development at ADC Therapeutics, said: “We are highly encouraged by these data which demonstrate the potential of ADCT-301 and ADCT-402. As we continue development, early indications are that our PBD-based ADCs could offer superior efficacy with a reduced resistance profile for the treatment of hematological tumors.”
The pre-clinical studies referenced above were conducted jointly by ADC Therapeutics, Spirogen (a division of AstraZeneca) and University College London, London.
ENDS
Notes to Editors
About ADC Therapeutics (www.adctherapeutics.com)
ADC Therapeutics SA (ADCT) is an oncology drug development company that specializes in the development of proprietary ADCs targeting major solid and hematological cancers. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to surface antigens present on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. The Company has access to warhead and linker chemistries via agreements with Spirogen (a wholly-owned subsidiary of AstraZeneca’s MedImmune). It is progressing eleven ADC programs, two of these under a joint development agreement with MedImmune. Its lead program, ADCT-301 for lymphoma and leukemia entered Phase I in 2015.
ADC Therapeutics has its head office in Lausanne, Switzerland and through subsidiaries has its R&D laboratories in London, UK, its clinical development team in New Jersey, USA, and its manufacturing team based in San Francisco, USA.
With its industry leading management team and board of directors, ADC Therapeutics is a leader in the development of PBD-based ADCs.
SOURCE: ADC Therapeutics
Post Views: 119
